Search - tctmd.com

Displaying 21 - 40 of 68

Sort: Relevancy | Date

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

Shelley Wood

December 30, 2022

News Daily News

Top General Cardiology and Prevention News of 2022

Michael O'Riordan

December 26, 2022

News Daily News

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Caitlin E. Cox

August 31, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

Shelley Wood

January 31, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Opinion Editor's Corner

The Biggest News of 2021: TCTMD’s Top 10

Shelley Wood

December 30, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

Advertisement

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

The Biggest News of 2022: TCTMD’s Top 10

Top General Cardiology and Prevention News of 2022

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Good News and Bad for High-Intensity Statin Use in ASCVD

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

TCTMD’s Top 10 Most Popular Stories for January 2022

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

The Biggest News of 2021: TCTMD’s Top 10

TCTMD’s Top 10 Most Popular Stories for December 2021

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content